Search Results - "Maeshima, Shuya"

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
  2. 2

    Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with small hepatocellular carcinoma treated by radiofrequency ablation by Ida, Yoshiyuki, Tamai, Hideyuki, Shingaki, Naoki, Shimizu, Ryo, Maeshima, Shuya, Maekita, Takao, Iguchi, Mikitaka, Terada, Masaki, Kitano, Masayuki

    Published in Cancer imaging (19-10-2020)
    “…Background .sup.18F-fluorodeoxyglucose (.sup.18F-FDG) uptake in hepatocellular carcinoma (HCC) is significantly associated with early recurrence and survival…”
    Get full text
    Journal Article
  3. 3

    Feeding artery ablation before radiofrequency ablation for hepatocellular carcinoma may reduce critical recurrence by Shimizu, Ryo, Tamai, Hideyuki, Ida, Yoshiyuki, Maeshima, Shuya, Shingaki, Naoki, Maekita, Takao, Iguchi, Mikitaka, Kitano, Masayuki

    Published in JGH open (01-04-2021)
    “…Background and Aim Percutaneous radiofrequency ablation (RFA) is a minimally invasive and curative local treatment for hepatocellular carcinoma (HCC). However,…”
    Get full text
    Journal Article
  4. 4

    Endoscopic ultrasound-guided radiofrequency ablation of porcine liver by Maeshima, Shuya, Ida, Yoshiyuki, Shimizu, Ryo, Kawaji, Yuki, Tamura, Takashi, Nuta, Junya, Hatamaru, Keiichi, Itonaga, Masahiro, Kudo, Masatoshi, Kitano, Masayuki

    Published in Journal of medical ultrasonics (2001) (01-07-2020)
    “…Purpose Animal studies of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) of the liver have rarely been reported. We assessed the effectiveness…”
    Get full text
    Journal Article
  5. 5

    Combination with portosystemic shunt occlusion and antiviral therapy improves prognosis of decompensated cirrhosis by Tamai, Hideyuki, Minamiguchi, Hiroki, Ida, Yoshiyuki, Shingaki, Naoki, Muroki, Tokuro, Maeshima, Shuya, Shimizu, Ryo, Okamura, Junpei, Koyama, Takao, Nakao, Taisei, Sonomura, Tetsuo

    Published in JGH open (01-08-2020)
    “…Background and Aim Portosystemic shunt occlusion using endovascular treatment can transiently improve liver function in patients with decompensated cirrhosis…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over by Tamai, Hideyuki, Shingaki, Naoki, Ida, Yoshiyuki, Shimizu, Ryo, Maeshima, Shuya, Okamura, Junpei, Kawashima, Akira, Nakao, Taisei, Hara, Takeshi, Matsutani, Hiroyoshi, Nishikawa, Izumi, Higashi, Katsuhiko

    Published in World journal of hepatology (27-09-2020)
    “…BACKGROUNDAlthough clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old…”
    Get full text
    Journal Article
  12. 12

    Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography in patients with small hepatocellular carcinoma treated by radiofrequency ablation by Ida, Yoshiyuki, Tamai, Hideyuki, Shingaki, Naoki, Shimizu, Ryo, Maeshima, Shuya, Maekita, Takao, Iguchi, Mikitaka, Terada, Masaki, Kitano, Masayuki

    Published in Cancer imaging (19-10-2020)
    “…F-fluorodeoxyglucose ( F-FDG) uptake in hepatocellular carcinoma (HCC) is significantly associated with early recurrence and survival after curative surgical…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15

    Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients by Tamai, Hideyuki, Shingaki, Naoki, Ida, Yoshiyuki, Shimizu, Ryo, Maeshima, Shuya, Okamura, Junpei, Kawashima, Akira, Nakao, Taisei, Hara, Takeshi, Matsutani, Hiroyoshi, Nishikawa, Izumi, Higashi, Katsuhiko

    Published in JGH open (01-12-2018)
    “…In September 2015, sofosbuvir and ledipasvir were approved for clinical use in Japan for patients infected with genotype 1 hepatitis C virus. We conducted a…”
    Get full text
    Journal Article
  16. 16